FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines

The FDA has announced the final design of its Expedited Investigational New Drug (IND) Pilot and is now accepting applications from sponsor-qualified research institution (QRI) pairs through October 30, 2026.¹

The pilot is part of Operation TrialBlazer, the Department of Health and Human Services initiative aimed at modernizing clinical development and restoring US competitiveness in early-stage research.

The timeline problem the pilot is designed to address is that first-in-human trials that may take up to two years to complete in the United States are completed significantly faster in China and Australia. The FDA frames this not only as a competitiveness issue but as a patient access problem: when trials move overseas, American patients lose the opportunity to participate in studies of investigational therapies, and the FDA's ability to oversee and shape the science diminishes.

Under the pilot, drug sponsors will apply alongside a prospective QRI, which can be an academic medical center, CRO, or other organization with the scientific and regulatory expertise to support IND preparation. QRIs will provide iterative, discipline-specific guidance to sponsors during the pre-IND phase, and the FDA will review and accept individual IND components on a rolling basis as they are completed rather than waiting for a full package.

The goal is to identify and resolve issues in real time, reducing the risk of a clinical hold during the standard 30-day IND review period.

The pilot also encourages earlier coordination of activities that typically follow IND submission, including institutional review board (IRB) review and clinical trial site activation. By bringing those processes into parallel rather than in sequence, the FDA aims to reduce the time between IND preparation and first patient enrollment.

The FDA expects to select eight to ten sponsor-QRI pairs for the initial cohort. The agency retains full regulatory authority throughout, including the authority to impose clinical holds and make all final determinations on whether a clinical investigation may proceed.

"The FDA greatly appreciates the public feedback we received on the proposed pilot, and we have incorporated that feedback into the final pilot design," said Michael Davis, MD, PhD, director of the FDA's Center for Drug Evaluation and Research (CDER), in an agency statement. "The FDA is committed to ensuring the United States remains the global standard for pharmaceutical innovation and regulatory rigor for the benefit of American patients and innovators."

Industry reaction: welcome, with conditions

Applied Clinical Trials covered the structural case for the pilot earlier in August, when Karim Mikhail, BPharm, MSc, acting director of the Center for Biologics Evaluation and Research (CBER), outlined in an FDA Voices post how over-submission driven by unclear phase-appropriate requirements, single pre-IND meetings expected to resolve multidisciplinary questions simultaneously, and post-IND delays in IRB review and site contracting were each compounding the timeline problem.²

Industry response to the formal launch has been cautiously supportive, with some noting that the pilot's value will depend on how far the proportionality principle extends.

Richard Graham, PhD, co-founder and chairman of the board of TruTechnologies, offered commentary to ACT via email that welcomed the attention to IRB review and site activation but pushed for a broader application of the same logic.

"The pilot could help make clearer what is actually required at a given stage of development and reduce work that does not add a commensurate safety benefit," Graham said. "But that thinking cannot stop at trial start-up. Clinical trial execution remains a major source of cost and delay, and proportionality has to extend into trial conduct more broadly."

He also argued that nonbinding guidance alone would not be sufficient to shift industry behavior.

"That will require both a carrot and a stick: a clearer regulatory roadmap for what constitutes meaningful risk and the oversight those risks warrant, along with real accountability for identifying and managing the risks that truly matter. Nonbinding guidance alone is not going to move the needle."

References

1. FDA Launches Expedited IND Pilot, Begins Accepting Applications. News release. FDA. September 15, 2026. Accessed September 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications?utm_medium=email&utm_source=govdelivery
2. FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership. Applied Clinical Trials. August 7, 2026. Accessed September 16, 2026. https://www.appliedclinicaltrialsonline.com/view/fda-overhauling-early-clinical-development-reclaim-us-leadership